News for ALVO Stock

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia® Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe Alvotech Annual General Meeting to be held June 25, 2025 Transactions of Managers and Closely Associated Persons Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm Trading in Alvotech’s Shares on Nasdaq Stockholm Commences Today Alvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm Transactions of Managers and Closely Associated Persons Transactions of Managers and Closely Associated Persons Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada   Transactions of Managers and Closely Associated Persons Strathmore Announces CSE Listing ACM Research Reports First Quarter 2025 Results Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025 Yoshiharu Reports First Quarter 2025 Financial Results Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET) Verizon Frontline provides critical Unmanned Aircraft Systems support for New Orleans PD during Mardi Gras Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer Alvotech Reports Record Results for 2024 and Provides Business Update UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab) Alvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida FRP Holdings, Inc. (NASDAQ: FRPH) Announces Results for the Fourth Quarter and Year Ended December 31, 2024 Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab) Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024 Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics Diane Leopold to Retire from Dominion Energy LAZYDAYS REPORTS THIRD QUARTER 2024 RESULTS Alvotech Reports Financial Results for the First Nine Months of 2024 Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024 European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio® AECOM to design the upgrade and expansion of the Walnut Creek Wastewater Treatment Plant Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024 European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) Graham Corporation Net Income Increased 12% to $3.0 Million on Expanded Gross Margin of 24.8% in First Quarter of Fiscal 2025 Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR SECOND QUARTER 2024 Concentra® to Announce Second Quarter 2024 Results on Thursday, August 1, 2024 STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe Oshkosh Corporation Appoints Angela M. Ambrose Vice President, Government Operations Genesis Energy, L.P. Declares Quarterly Distribution Alvotech Announces Closing of Private Debt Financing Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Alvotech Issues New Shares to Holders of Convertible Bonds Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024 Alvotech Receives Conversion Notices for Majority of Convertible Bonds Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe Alvotech and STADA add to Strategic Alliance through Denosumab Partnership Alvotech Announces Strategic Refinancing Agreement Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. Alvotech S.A. Annual General Meeting to be held June 7, 2024 UCLOUDLINK GROUP INC. Announces Unaudited First Quarter 2024 Financial Results Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT) Alvotech Announces Participation at BofA Securities Healthcare Conference 2024 U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab) Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab) Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX CHIPOTLE BURRITOS GO GREEN IN AUGUSTA, GA TO KICK-OFF GOLF'S BIGGEST TOURNAMENT Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024 Alvotech Announces Increase in Number of Own Shares Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update The ONE Group Hospitality, Inc. to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast at 4:30 PM ET on March 14, 2024 Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET Alvotech Appoints Interim Chief Quality Officer Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab) Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04 STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept) Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development Lone Wolf integrates mortgage partners into real estate's top transaction management solution to deliver an end-to-end, fully connected mortgage experience Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update Alvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET Alkermes Celebrates #Movember for Men’s Health Awareness Month Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab) Viper Energy Launches Secondary Common Stock Offering By Certain Stockholders and Concurrent Stock Repurchase STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara Alvotech to Present at the Jefferies 2023 London Healthcare Conference Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference Alvotech Announces Changes to the Leadership Team Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET Alvotech Completes $100 Million Convertible Bond Private Placement Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02 Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara® Alvotech to Participate in Jefferies Healthcare Conference Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept) Alvotech S.A. Annual General Meeting to be held June 6, 2023 Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer Complete Response Letter Received for AVT02 Biologics License Application Alvotech Provides Regulatory Update on AVT02 Biologics License Application Alvotech Provides Update on Corporate Sustainability Framework Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023 Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market Settlement of Alvotech Private Share Placement Completed EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) Alvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair® (omalizumab) Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia Alvotech Completes $137 Million Private Share Placement Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® Alvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria® Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira® Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT to headline field Alvotech Completes $59.7 Million Private Placement Alvotech Shares Start Trading on Nasdaq Iceland Main Market Alvotech and STADA Broaden Access to Hukyndra® adalimumab biosimilar in Europe Nasdaq Iceland Approves the Request for Trading of Alvotech’s Shares on the Main Market Alvotech Announces Changes to its Leadership Team Alvotech Submits its Application for Admission of the Company’s Shares to Trading on Nasdaq Iceland Main Market Alvotech Secures Financing Facilities of Approximately $136 Million Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira® Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022 Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan Alvotech Appoints Sarah Tanksley as Chief Quality Officer Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra® Alvotech Reports Update on Initial AVT02 Biologics License Application Alvotech Reports Update on Initial AVT02 Biologics License Application Alvotech Reports First Half 2022 Financial Results and Business Update Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021 Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 Alvotech to Participate in Two Upcoming Investor Conferences in September 2022 Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company’s Proposed Generic to Xifaxan® for IBS-D Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva® Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®   Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea® Increase of share capital and creation of treasury share pool to meet obligations with respect to Warrants issued by Alvotech, the Management Incentive Plan, as well as option to issue shares pursuant to the SEPA facility with Yorkville Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland Supplement to the Company Description Publication of a Company Description and Intended Listing on First North Iceland